TC Biopharm (Holdings) Statistics
Total Valuation
TCBPY has a market cap or net worth of 231,336. The enterprise value is 586,685.
| Market Cap | 231,336 |
| Enterprise Value | 586,685 |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TCBPY has 2.10 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 2.10M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 12.08% |
| Float | 2.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.06 |
| P/TBV Ratio | 0.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.04 |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.39 |
| Quick Ratio | 0.45 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -426.84% and return on invested capital (ROIC) is -178.14%.
| Return on Equity (ROE) | -426.84% |
| Return on Assets (ROA) | -92.84% |
| Return on Invested Capital (ROIC) | -178.14% |
| Return on Capital Employed (ROCE) | -306.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -390,152 |
| Employee Count | 39 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -816,219 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.85% in the last 52 weeks. The beta is 0.47, so TCBPY's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -98.85% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 42.56 |
| Average Volume (20 Days) | 14,305 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.05M |
| Pretax Income | -16.03M |
| Net Income | -15.22M |
| EBITDA | -15.51M |
| EBIT | -16.05M |
| Earnings Per Share (EPS) | -161.24 |
Balance Sheet
The company has 1.52 million in cash and 1.88 million in debt, giving a net cash position of -355,350 or -0.17 per share.
| Cash & Cash Equivalents | 1.52M |
| Total Debt | 1.88M |
| Net Cash | -355,350 |
| Net Cash Per Share | -0.17 |
| Equity (Book Value) | 3.77M |
| Book Value Per Share | 5.91 |
| Working Capital | 2.04M |
Cash Flow
In the last 12 months, operating cash flow was -15.73 million and capital expenditures -79,622, giving a free cash flow of -15.81 million.
| Operating Cash Flow | -15.73M |
| Capital Expenditures | -79,622 |
| Free Cash Flow | -15.81M |
| FCF Per Share | -7.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCBPY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6,577.42% |
| FCF Yield | -6,835.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 10, 2025. It was a reverse split with a ratio of 0.05.
| Last Split Date | Feb 10, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |